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The reliability of DrugWipe 5A on site test for principal drugs of abuse (cannabis, amphetamines, cocaine, and opiates)
detection in oral fluid was assessed by comparing the on-site results with headspace solid-phase microextraction (HS-SPME)
gas chromatography-mass spectrometry (GC-MS) analysis on samples extracted by the device collection pad. Oral fluid samples
were collected at recreational settings (e.g., discos, pubs, and music bars) of Rome metropolitan area. Eighty-three club goers
underwent the on-site drug screening test with one device. Independently from the result obtained, a second device was used
just to collect another oral fluid sample subsequently extracted and analyzed in the laboratory following HS-SPME procedure, gas
chromatographic separation by a capillary column, and MS detection by electron impact ionization. DrugWipe 5A on-site test
showed 54 samples (65.1%) positive to one or more drugs of abuse, whereas 75 samples (90.4%) tested positive for one or more
substances following GC-MS assay. Comparing the obtained results, the device showed sensitivity, specificity, and accuracy around
80% for amphetamines class. Sensitivity (67 and 50%) was obtained for cocaine and opiates, while both sensitivity and accuracy
were unsuccessful (29 and 53%, resp.) for cannabis, underlying the limitation of the device for this latter drug class.
1. Introduction
There has been increasing interest regarding a variety of
alternative biological matrices such as oral fluid, sweat, and
hair in the last few years [1, 2]. Specifically, oral fluid shows
several advantages in the on-site screening for drug use.
The collection is noninvasive and easy to perform; it can
be achieved in privacy, under close supervision, thereby
reducing any opportunity of sample adulteration [3].
Furthermore, oral fluid reflects blood-drug concentra-
tions due to the correlation between kinetics of several drugs
in the blood and oral fluid, suggesting recent drug use.
Recent data have demonstrated an improvement in some
on-site drug testing to disclose current consumption of illicit
drugs. This significant progress in the sample collection and
the improved accuracy of analysis have determined a certain
success of on-site tests on oral fluid [4–9].
Although international literature suggests that the man-
ufacturers overstate the capabilities of on-site testing devices
to detect drugs in oral fluids, a number of new on-site testing
devices have been constantly developed [10–16].
These devices are being used in many countries to
perform on-site testing on oral fluid controls in Driving
Under the Influence of Drugs (DUID) [5, 7, 10, 11, 13, 15]
and several recent publications demonstrate that oral fluid
screening devices are becoming more robust and reliable
[12, 17–20].
In Italy, since August 2010, the law has considered oral
fluid as an alternative biological specimen for the determina-
tion of DUID. Specifically, the devices can be used for rapid
on-site testing as a first screening [21].
Among the developed devices, DrugWipe is an imm-
unochromatographic test strip, based on the Frontline urine
test strip from Boehringer Mannheim (F. Hoffmann-La
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Roche, Basel, Switzerland) [22]. A pink colour in the test
window indicates the presence of the analyte to which the test
is specifically addressed and different devices are needed for
the detection of each class of drugs of abuse. A recent version
of this device, DrugWipe 5A, can simultaneously reveal
the presence of cannabis, amphetamine, methamphetamine,
ecstasy, cocaine, and opiates in oral fluid of consumers. In
detail, the device is divided into two parts with two different
collection pads: one for opiates and cocaine and the other for
amphetamines and cannabis.
Here is reported our experience with application ofDrug-
Wipe 5A on-site oral fluid testing in recreational settings,
subsequent oral fluid collection, and quantitative detection of
opiates, cocaine, amphetamines, and cannabis during preven-
tive actions carried out by a nongovernmental organization
(NGO) against drug use in recreational settings (e.g., discos,
pubs, and music bars) of Rome metropolitan area (Lazio,
Italy).
The study’s aim was to verify the reliability of DrugWipe
5A device for an on-site drug screening andwhether a second
device could be used as a simple collector for a subsequent
confirmatory chromatographic-mass spectrometric assay.
Specifically, easy and low-cost solvent-free headspace solid-
phase microextraction and gas chromatography-mass spec-
trometry for drugs abuse (amphetamines, opiates, cocaine,
and cannabinoids) in oral fluid directly collected by the
device pad has been used. The method has been applied
in real cases of 83 drivers stopped during roadside con-
trols.
2. Experimental
2.1. Chemicals, Reagent, and Device. Codeine, morphine, 6-
monoacetylmorphine (6-MAM), codeine-d
3
, morphine-d
3
,
6-monoacetylmorphine-d
3
, amphetamine (A), methamphet-
amine (MA), methylenedioxyamphetamine (MDA), methyl-
enedioxymethamphetamine (MDMA), methylenedioxyeth-
amphetamine (MDE), N-methyl-1-(1,3-benzodioxol-5-yl)-2-
butanamine (MBDB), ketamine, methadone, cocaine, cocae-
thylene, Δ9-Tetrahydrocannabinol (THC), 3,4-methylenedi-
oxypropylamphetamine (MDPA), cocaine-d
3
(COC-d
3
),Δ8-
Tetrahydrocannabinol (Δ8THC), N-Methyl-N-(trimethyls-
ilyl)trifluoroacetamide (MSTFA), N,O-bis(trimethylsilyl)tri-
fluoroacetamide (BSTFA), and trimethylchlorosilane
(TMCS) were purchased from Sigma Aldrich (Milan,
Italy).
Ultrapure water was obtained from a Milli-Q Unit
(Millipore, Bedford, MA, USA). Acetic anhydride, sodium
hydroxide (NaOH), hydrochloric acid (HCl), sodium chlo-
ride (NaCl), potassium carbonate (K
2
CO
3
), and acetone of
analytical grade were purchased from Carlo Erba (Milan,
Italy).
A solid-phase microextraction SPME Holder (manual)
assembly with a replaceable extraction fibre coated with
100 𝜇m polydimethylsiloxane (PDMS) and a 110VAC block
heater purchased from Sigma-Aldrich were used. DrugWipe
5A devices were provided by Securetec (Brunnthal, Ger-
many).
2.2. Subjects and Oral Fluid Testing with DrugWipe 5A.
During preventive actions (January to March 2015) carried
out by NGO in the five principal discos, pubs, and music
bars of Romametropolitan area, 83 young people were tested
with the DrugWipe 5A oral fluid screening device obtained
from Securetec (Brunnthal, Germany).The participants were
informed on the purpose of sample collection, and they gave
signed consent to the collection and subsequent anonymous
analysis of their oral fluid.
NGO staff performed oral fluid screening tests by wiping
the tongue of the drug users 5–10 times with the collection
pad, as recommended by the manufacturing instructions.
After the sampling, the collection pad was put into direct
contact with the drug test strip. Drug test and validity results
were visually read after 10minutes. Two coloured lines, one in
the upper control window and one in the lower test window,
indicate a positive result. Cut-off values for different drug
groups provided by the manufacturer were the following:
amphetamines, 50 ng/mL; methamphetamines, 25 ng/mL;
MDMA, 25 ng/mL; cocaine, 30 ng/mL; opiates, 10 ng/mL; and
cannabis, 30 ng/mL.
Another oral fluid sample was collected using DrugWipe
5A and the two collection pads were mailed to the analytical
laboratory and stored at ambient temperature without any
preservative until HS-SPME-GC-MS analysis was performed
(for a maximum of 14 days).
In both cases of positive and negative results to the first
screening test on oral fluid byDrugWipe 5A, a second sample
was collected for chromatographic analysis.
2.3. Calibration Standards. Stock solutions of each analyte
(1mg/mL) were combined and diluted with methanol to set
working calibrator solutions (0.01, 0.02, 0.05, 0.10, 1.00, and
2.00 𝜇g/mL). Working internal standard methanol solutions
at 2 𝜇g/mL were also prepared. Stock solutions were stored
at −20∘C until use. Blank oral fluid samples were obtained
by wiping the tongue of laboratory staff 5–10 times with the
DrugWipe 5A test pad.
Oral fluid calibrations were prepared by spiking 5𝜇L of
working calibrator solutions and internal standard solutions
directly onto the test pad area of the blank sample.
Quality control samples of 0.075 ng/pad (low control),
0.15 ng/pad (medium control), and 0.45 ng/pad (high con-
trol) for THC and 0.45 ng/pad (low control), 2.00 ng/pad
(medium control), and 4.00 ng/pad (high control) for other
drugs of abuse were prepared in the same oral fluid drug-
free pad and stored until analysis.They were included in each
analytical batch to check calibration, accuracy and precision,
and stability of samples under storage conditions.
Although recently some authors claim the volume to
be about 20𝜇L [23], other authors reported that limited or
unknown collection volume from the collection devicemight
create a number of difficulties for the laboratory [24, 25]. For
this reason, the concentration of the analytes was expressed
in ng substance/pad.
2.4. Oral Fluid Analysis. Oral fluid samples collected by a
second DrugWipe 5A device were analyzed by headspace
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solid-phase microextraction (HS-SPME) and gas chroma-
tography-mass spectrometry (GC-MS) procedures according
to Merola et al. [26] and Moller et al. [27]. In particular,
although ketaminewas not among the substances screened by
DrugWipe,HS-SPME-GC-MS investigated it for information
on current drug consumption.
For the analysis of opiates, the first pad was removed
and extracted with 200𝜇L methanol in a closed headspace
vial (2mL), containing internal standard solution (5 𝜇L of
2 𝜇g/mL codeine-d
3
, morphine-d
3
, and 6-monoacetylmor-
phine-d
3
). The sample was incubated for 60min at 60∘C.
The methanol extract was transferred to a 10mL vial and
dried under nitrogen flow, 10𝜇L BSTFA + 1% TMCS were
added, and the SPME needle was introduced into the vial and
exposed to adsorption for 30min at 125∘C. Finally, thermal
desorption of the fibre was performed at 250∘C for 3min
inside the GC.
For cocaine, ketamine, and amphetamines, the second
pad was removed and extracted with 200 𝜇L 1M HCl in a
closed headspace vial (20mL), containing internal standards
(5 𝜇L of 2𝜇g/mL MDPA, COC-d
3
, MDPA, and Δ-8 THC).
The sample was incubated for 60min at 60∘C.
After cooling at room temperature, the extracted acid
layer was transferred to another vial (2mL) containing
200mg K
2
CO
3,
the SPME needle was introduced, and the
fibrewas exposed to adsorption for 10min at 90∘C; 5 𝜇L acetic
anhydride was added, and the SPME needle was introduced
into a second vial and exposed for 3min at 90∘. Thermal
desorption was performed at 250∘C for 3min inside the GC.
For THC extraction, 1mLNaOH 1M and 0.5 g NaCl were
added to the vial containing the pad previously used; the
SPME needle was introduced into the vial and exposed to
adsorption for 30min at 150∘C. For derivatization, 5𝜇L of
MSTFA was added and the fibre was exposed for 10min at
90∘C. Thermal desorption was performed at 250∘C for 3min
inside the GC.
2.5. GC-MS Analysis. A Gas Chromatography 6890 Plus
and Mass Selective Detector 5973N (Hewlett-Packard, Palo
Alto, CA, USA) equipped with a J&W 19091S-101 HP-5MS
Trace Analysis capillary column (5% PH ME Siloxane; film
thickness, 0.33 𝜇m; length, 12.5m; column ID, 0.20mm) was
used. The column temperature was initially held at 60∘C for
2min and then raised 20∘C/min to reach 250∘C and finally
held at 250∘C for 5min. The temperature of the injection
port, ion source, and transfer line was set at 250∘C, 230∘C,
and 280∘C, respectively. Thermal desorption was performed
at 250∘C for 3min inside the gas chromatograph. Heliumwas
used as carrier gas at a flow rate of 0.7mL/min. The splitless
injection mode was used. The mass spectrometer uses elec-
tron impact ionization. The mass spectra were collected by
total ion chromatography. Identification criteria were based
on retention time (RT) ±0.02min with respect to the samein
spiked oral fluid sample and on the relative abundance of the
three confirming ions with respect to the target. Quantitative
data were obtained by selected ion monitoring for each
compound and for internal standards (IS). Monitored ions
and RT for each compound are shown in Table 1.
Table 1: Monitored ions and retention time (RT) for drugs of abuse
in oral fluid samples by HS-SPME-GC-MS.
Compound RT (min) Ion𝑚/𝑧(relative abundance)
A 9.32 86, 91, 118
MA 9.37 58, 91, 100
MDA 11.32 162, 135, 221
Ketamine 11.36 180, 182, 209
MDMA 11.75 58, 100, 162
MDE 11.96 72, 114, 162
MBDB 12.07 72, 114, 176
MDPA (IS)∗∗ 12.34 86, 128, 162
Methadone 13.03 72, 91, 294
COC-d
3
(IS)∗∗ 13.48 85, 185, 306
Cocaine 13.50 82, 182, 303
Cocaethylene 13.96 196, 272, 317
Δ8THC (IS)∗∗ 14.52 303, 330, 386
Δ9THC 14.71 303, 371, 386
Codeine 16.95 178, 196, 371
Codeine-d
3
(IS)∗∗ 16.99 181, 199, 374
Morphine 17.70 236, 401, 429
Morphine-d
3
(IS)∗∗ 17.73 239, 404, 432
6-MAM 18.17 340, 357, 399
MAM-d
3
(IS)∗∗ 18.19 343, 360, 402
A, amphetamine; MA, methamphetamine; MDA, methylenedioxyamphet-
amine; MDMA, methylenedioxymethamphetamine; MDE, methylenedio-
xyethamphetamine; MBDB, N-methyl-1-(1,3-benzodioxol-5-yl)-2-butan-
amine; THC, Δ9-Tetrahydrocannabinol; MDPA, 3,4-methylenedioxypro-
pylamphetamine; COC-d3, cocaine-d3; Δ8THC, Δ8-Tetrahydrocannabinol;
6-MAM, 6-monoacetylmorphine.
∗∗IS: internal standard.
Quantifier ions are in bold.
2.6. GC-MS Method Validation. Validation protocol applied
in the present study included linearity, limit of detection
(LOD), limit of quantification (LOQ), precision, accuracy,
and stability as reported elsewhere [28–30].
Linearity was determined by least-squares regression
with 1/𝑥2 weighting of the following concentration: 0.05, 0.1,
0.25, 0.50, and 1.00 ng/pad for THC and 0.25, 0.50, 1.00, 2.50,
and 5.00 ng/pad for the other analytes. Acceptable linearity
was achieved when the coefficient of determination was at
least 0.99.The LOD and LOQwere evaluated with decreasing
analyte concentrations in drug-spiked oral fluid samples.The
LODwas defined as the lowest concentration with acceptable
chromatography, the presence of all transitions with signal-
to-noise ratios of at least 3, and a retention time within
±0.2min of the average retention time of the calibrator. LOQ
was the lowest concentration that met LOD criteria and a
signal-to-noise ratio of at least 10.
Precision, accuracy, and analytical recovery were calcu-
lated from five different daily replicates for five different days
of 0.075, 0.15, and 0.45 ng/pad for THC and 0.45, 2.00, and
4.00 ng/pad for other drugs of abuse.
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Table 2: Linearity of the HS-SPME-GC-MS procedure for compounds under investigation.
Compounds Slope Intercept 𝑅2 LOD (ng/pad) LOQ (ng/pad) Analytical recovery (%)
A 0.64 0.07 0.995 0.37 1.11 100.8
MA 2.08 0.20 0.990 0.68 2.04 99.2
MDA 1.93 −0.16 0.988 0.60 1.80 88.8
Ketamine 6.47 −1.16 0.990 0.73 2.19 84.4
MDMA 5.57 0.86 0.996 0.34 1.02 100.8
MDE 5.73 0.14 0.998 0.26 0.78 103.2
MBDB 8.34 0.77 0.999 0.11 0.33 98.8
Methadone 9.74 −1.46 0.990 0.71 2.13 85.5
Cocaine 6.18 0.05 0.996 0.35 1.05 107.6
Cocaethylene 2.01 −0.42 0.992 0.51 1.53 90.4
THC 10.52 0.03 0.990 0.06 0.18 102.0
Codeine 4.73 0.63 0.996 0.06 0.18 96.0
Morphine 7.32 2.05 0.995 0.43 1.29 96.4
6-MAM 9.52 3.74 0.993 0.39 1.17 105.6
A, amphetamine; MA, methamphetamine; MDA, methylenedioxyamphetamine; MDMA, methylenedioxymethamphetamine; MDE, methylenedioxyetham-
phetamine; MBDB, N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine; THC, Δ9-Tetrahydrocannabinol; 6-MAM, 6-monoacetylmorphine.
Stability of analytes in the device pad was tested in
triplicate at 0.50 ng/pad for THC and 5.00 ng/pad for other
drugs of abuse left in the dark at room temperature for 7 and
14 days and then analyzed by HS-SPME-GC-MS.
2.7. Interpretation of theDrugWipe 5AResults. Theevaluation
of the results is based on classification into the following
categories: true positive (TP), cases with a positive DrugWipe
5A test result and a positive HS-SPME-GC-MS analysis
result; false positive (FP), cases with a positive DrugWipe 5A
test result and a negative GC-MS analysis result; true negative
(TN), cases with a negative DrugWipe 5A test result and a
negative GC-MS analysis result; false negative (FN), cases
with a negative DrugWipe 5A test result and a positive HS-
SPME-GC-MS analysis result.
Taking into consideration the above classification, sensi-
tivity, specificity, and accuracy of the DrugWipe 5A oral fluid
were calculated as follows. Sensitivity = (TP/TP+FN∗100).
Specificity = (TN/TN + FP ∗ 100). Accuracy = (TP +
TN/number of tests) [12, 15].
3. Results and Discussion
3.1. Validation Results. Linear calibration curves were
obtained for the compounds under investigation with
correlation coefficients (𝑅2) of at least 0.99 in all cases and
LODs and LOQs values adequate for the purpose of the
present study (Table 2).
Intraday and interday precision and accuracy of the ana-
lytes under investigation satisfactorilymet the internationally
established acceptance criteria and were always better than
15% (Table 3) and recovery ranged from 84.4% to 107.6% for
the different compounds (Table 2).
With respect to stability test (Table 4), in samples stored in
the dark, at room temperature, a maximum decrease of about
15% initial concentration was observed for amphetamines,
cocaine, and opiates after 14 days. Conversely, in case of THC,
a decrease of 50% initial concentration was already observed
after seven days and it remained stable at the same percentage
after fourteen days. This is in agreement with Crouch’s study
on the effects of the oral fluid collection device on THC
concentration and on its stability [24]. For instance, apart
from THC instability, the device pad resulted to be a reliable
tool for oral fluid collection, which could be mailed and
stored at ambient temperature for a maximum of 14 days.
3.2. Samples Analysis. In order to demonstrate the usefulness
of the device DrugWipe 5A, the results obtained by the device
were compared to the ones obtained by HS-SPME-GC-MS in
eighty-three clubs goers. In case of HS-SPME-GC-MS, only
substances detected by this assay were reported in Table 5.
The results of DrugWipe 5A analysis showed that 54
samples (65.1%) were positive to one or more substances: 8
were found to be positive to cannabis, 16 were found to be
positive to amphetamines, and 8 were found to be positive
to cocaine. Eight samples were positive to amphetamines
and THC, 5 samples were positive to both amphetamines
and cocaine, 2 samples were positive to THC and opiates, 3
samples were positive to cocaine and opiates, 1 sample was
positive to amphetamines and opiates, and 3 samples were
positive to amphetamines, cocaine, and opiates.
In the HS-SPME-GC-MS analysis, 75 samples (90.4%)
were positive for one or more substances: 35 were polydrug
users, 21 were positive only for THC (ranged concentration:
<LOQ—11.82 ng/pad), 7 were positive for MDMA (ranged
concentration: <LOQ—184.08 ng/pad), 8 were positive for
cocaine (ranged concentration:<LOQ—1398.05 ng/pad), and
4 were positive for ketamine (ranged concentration: <LOQ—
9.09 ng/pad), even if this substance was not included in
DrugWipe screening.
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Table 4: Stability results at room temperature after 7-day and 14-day
test.
Analyte 7-day test (%) 14-day test (%)
A 96.0 85.0
MA 95.2 84.8
MDA 95.0 85.3
Ketamine 97.9 88.9
MDMA 96.0 85.1
MDE 95.6 84.9
MBDB 95.9 84.9
Methadone 99.7 88.9
Cocaine 99.9 86.1
Cocaethylene 98.5 85.1
THC 51.0 50.0
Codeine 98.5 89.1
Morphine 98.0 89.0
6-MAM 97.9 88.7
A, amphetamine; MA, methamphetamine; MDA, 3,4-methylenedioxyam-
phetamine; MDMA, 3,4-methylenedioxymethamphetamine; MDEA, 3,4-
methylenedioxy-N-ethylamphetamine; MBDB, N-methyl-1-(1,3-benzodio-
xol-5-yl)-2-butanamine; THC, Δ9-Tetrahydrocannabinol.
DrugWipe 5A performance data (true positive, true
negative, false positive, and false negative results) reported
in Table 6 compared the device results with those obtained
by HS-SPME-GC-MS and showed sensitivity, specificity, and
accuracy of the device with respect to the different drug class.
The comparison between on-site and laboratory results
confirmed the different reliability for each class of substances,
as already reported in the literature [31].
From the obtained results, it can be said that the device
performed quite well in detecting the amphetamines class,
with sensitivity, specificity, and accuracy around 80% value.
The second best results were obtained in case of cocaine
which showed good specificity and accuracy but worse sen-
sitivity. In this concern, previous studies demonstrated that
cocaine was predominantly found in oral fluid with respect to
its principal metabolite benzoylecgonine, present in very low
concentrations in this biological matrix [3, 9]. Furthermore,
recently, it has been demonstrated that oral fluid concentra-
tion of benzoylecgonine and the relationship with cocaine are
time dependent, unless cocaine is intravenously administered
[32]. Since benzoylecgonine extraction by HS-SPME and
detection would have presented a great analytical difficulty
due to its polar nature, this metabolite was not considered
in this study. Indeed, for the reported reasons, its detection
would not have increased the number of samples positive to
cocaine.
In case of opiates, an even poorer sensitivity value was
calculated. The low prevalence for opiates in the studied
group of drivers did not allow a proper evaluation of the
performances of DrugWipe 5A for these substances.
Finally, in agreement with previous observations [13, 16],
our results highlight the unsuccessful detection of THC by
DrugWipe 5A device for oral fluid.
Observations by NGO staff and some laboratory test
simulations have confirmed that the line test for cannabis
is usually very weak and delayed [25]. This difficulty in
interpreting the resultsmay give rise to a high number of false
negatives.
The comparison between device cut-offs with HS-SPME-
GC-MS results confirms the high specificity (always >80%)
for all class of substances and the poor sensitive value for
opiates (about 67%) andTHC (about 30%). On the other side,
we observed an increase of sensitivity of both amphetamines
(about 92%) and cocaine (about 80%).
Outside the principal aim of the study, our results evi-
denced a nonnegligible 20.5% of our clubs goers consuming
ketamine. To the best of our knowledge, this is the first time
the objective assessment of the consumption of this drug has
been performed in oral fluid samples from a population of
Italian disco goers. Significant limitation of on-site oral fluid
test devices is that they cannot usually detect increasing num-
ber of new psychoactive drugs. Ketamine is only one of them.
This is an issue that should be taken into account, especially
when the device is applied at recreational settings, where the
use of new drugsmay be likely. It can be underlined that study
limitation could lie in the fact that HS-SPME-GC-MS assay
was not carried out in real oral fluid samples but precisely
on extracts of collection pad. Nevertheless, this occurrence
allowed a direct comparison of the immunochromatographic
screening test and a confirmatory gas chromatographic-
mass spectrometric assay on the same collected substrate.
In addition, only eighty-three samples have been analyzed
which cannot be conclusive but can be an eye opener on
the reliability of this simple and easily applicable on-site test
device for oral fluid drug testing.
4. Conclusions
From the results obtained in the present study, DrugWipe 5A
device has been shown to be a practical, easy way of sampling
and a non-time-consuming procedure for screening drug of
abuse testing in oral fluid. The device has proven to be not
sensitive and accurate enough for cannabis but acceptable for
other drugs of abuse. Although oral fluid may be a useful
matrix for on-site testing of drugged drivers, it is evident
that it still shows a lack of sensitivity and, to ensure adequate
reliability, GC-MS or LC-MS confirmation of on-site oral
fluid screening tests remains necessary, due to the presence
of a significant number of false negative and false positive
results, even when using the commercial kit with the best
performance.
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Table 6: Performance data ofDrugWipe 5A in comparisonwithHS-
SPME-GC-MS results.
Cannabis Amphetamines Cocaine Opiates
TP 14 26 16 2
FP 4 7 3 7
TN 30 43 56 72
FN 35 7 8 2
Number of tests 83 83 83 83
Sensitivity (%) 29 79 67 50
Specificity (%) 88 86 95 91
Accuracy (%) 53 83 87 89
TP, true positive; FP, false positive; TN, true negative; FN, false negative.
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